keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ATWLPPR Peptide is a biologically active peptide functioning as a specific antagonist to VEGFR2/KDR. It binds to VEGFR2 (KDR/flk), thereby completely inhibiting VEGF binding to KDR and blocking VEGF-induced angiogenesis in vivo. Moreover, it selectively inhibits human endothelial cell proliferation in vitro and effectively abolishes VEGF-induced angiogenesis in vivo.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | ATWLPPR Peptide is a biologically active peptide functioning as a specific antagonist to VEGFR2/KDR. It binds to VEGFR2 (KDR/flk), thereby completely inhibiting VEGF binding to KDR and blocking VEGF-induced angiogenesis in vivo. Moreover, it selectively inhibits human endothelial cell proliferation in vitro and effectively abolishes VEGF-induced angiogenesis in vivo. |
Molecular Weight | 839.98 |
Formula | C40H61N11O9 |
CAS No. | 272121-15-0 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ATWLPPR Peptide 272121-15-0 inhibitor inhibit